|
|
| Research article summary (published Sep 2009): |
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.
Full Abstract
The endocannabinoid system has emerged as a significant player in the control of energy balance and metabolism, through its direct central and peripheral effects, as well as via its interaction with other appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is overactive in obesity and were it possible to safely dampen-down the elevated endocannabinoid tone, lipid and carbohydrate profiles could be improved and weight loss induced. The series of randomised clinical trials showed reproducible beneficial effects on weight, HbA1c and lipid parameters, in addition to other cardiovascular risk factors. However, to date, clinical developments have been halted because of psychiatric side effects. Although recent evidence has highlighted the importance of an appetite-independent, peripheral mode of action, it is still unclear whether selectively blocking the peripheral system could potentially solve the problem of the central side effects, which thus far has led to the demise of the cannabinoid antagonists as useful pharmaceuticals. In this concise review, we summarise the data on the metabolic effects of the cannabinoid pathway and its antagonists.
Author information
Author/s: Butler, Helen (H); Korbonits, Márta (M);
Affiliation: Department of Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Grants: 081922/Z/07/Z (Agency:Wellcome Trust)
Journal and publication information
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
Journal: European journal of endocrinology / European Federation of Endocrine Societies (Eur J Endocrinol), published in England. (Language: eng)
Reference: 2009-Nov; vol 161 (issue 5) : pp 655-62
Dates: Created 2009/10/16; Completed 2009/11/13;
PMID: 19729432, status: MEDLINE (last retrieved date: 11/15/2009)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MeSH Headings (categories) shown below.
Note: Bold headings indicate primary MeSH headings or qualifiers.
Associated Chemicals: Anti-Obesity Agents (0) ; Cannabinoids (0) ; Endocannabinoids (0) ; Receptors, Cannabinoid (0)Related articles
These are the most related articles currently in our database:
- Cannabinoid receptor antagonists and obesity.
30 Mar 2004 - Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
26 Dec 2006 - [Endocannabinoid and endocannabinoid receptor antagonists]
30 Jan 2005 - The endocannabinoid system: body weight and metabolic regulation.
30 Dec 2005 - Endocannabinoid receptor antagonists: potential for obesity treatment.
30 Dec 2003 - S 23521 decreases food intake and body weight gain in diet-induced obese rats.
29 Sep 2004 - Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases.
3 Oct 2006 - Endocannabinoids: biology, mechanism of action and functions.
30 Mar 2006 - Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies?
30 Dec 2007 - [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]
30 Dec 2004
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a larger map of 100+ related articles.